Search research articles
Contact Us
Filters
Showing results (71-80 of 99) with videos related to
Page
of 10
Sort By:
BJU International
|
April 3, 2016
Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy
Matthias M Heck, Markus A Thaler, Sebastian C Schmid, et al.
European Urology
|
December 9, 2020
Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA
Benedikt Feuerecker, Robert Tauber, Karina Knorr, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
December 4, 2013
Prospective comparison of computed tomography, diffusion-weighted magnetic resonance imaging and [11C]choline positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer patients
Matthias M Heck, Michael Souvatzoglou, Margitta Retz, et al.
Prostate Cancer and Prostatic Diseases
|
September 26, 2020
KLK3 and TMPRSS2 for molecular lymph-node staging in prostate cancer patients undergoing radical prostatectomy
Lukas Lunger, Margitta Retz, Miriam Bandur, et al.
The Journal of Urology
|
April 9, 2021
Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice
Axel S Merseburger, Daniel Castellano, Thomas Powles, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
September 24, 2016
Radiation Dosimetry for <sup>177</sup>Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions
Shozo Okamoto, Anne Thieme, Jakob Allmann, et al.
Acta Oncologica (Stockholm, Sweden)
|
November 5, 2021
Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study
Manuela Schmidinger, Robert J Motzer, Frederic Rolland, et al.
Oncology Reports
|
May 3, 2014
German second-opinion network for testicular cancer: sealing the leaky pipe between evidence and clinical practice
Friedemann Zengerling, Michael Hartmann, Axel Heidenreich, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 12, 2018
SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11)
Margitta Retz, Jens Bedke, Martin Bögemann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 9, 2005
Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95)
Jan Lehmann, Margitta Retz, Christina Wiemers, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 99) with videos related to
Sort By:
Page
of 10
BJU International
|
April 3, 2016
Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy
Matthias M Heck, Markus A Thaler, Sebastian C Schmid, et al.
European Urology
|
December 9, 2020
Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA
Benedikt Feuerecker, Robert Tauber, Karina Knorr, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
December 4, 2013
Prospective comparison of computed tomography, diffusion-weighted magnetic resonance imaging and [11C]choline positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer patients
Matthias M Heck, Michael Souvatzoglou, Margitta Retz, et al.
Prostate Cancer and Prostatic Diseases
|
September 26, 2020
KLK3 and TMPRSS2 for molecular lymph-node staging in prostate cancer patients undergoing radical prostatectomy
Lukas Lunger, Margitta Retz, Miriam Bandur, et al.
The Journal of Urology
|
April 9, 2021
Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice
Axel S Merseburger, Daniel Castellano, Thomas Powles, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
September 24, 2016
Radiation Dosimetry for <sup>177</sup>Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions
Shozo Okamoto, Anne Thieme, Jakob Allmann, et al.
Acta Oncologica (Stockholm, Sweden)
|
November 5, 2021
Analysis by region of outcomes for patients with advanced renal cell carcinoma treated with cabozantinib or everolimus: a sub-analysis of the METEOR study
Manuela Schmidinger, Robert J Motzer, Frederic Rolland, et al.
Oncology Reports
|
May 3, 2014
German second-opinion network for testicular cancer: sealing the leaky pipe between evidence and clinical practice
Friedemann Zengerling, Michael Hartmann, Axel Heidenreich, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 12, 2018
SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11)
Margitta Retz, Jens Bedke, Martin Bögemann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 9, 2005
Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95)
Jan Lehmann, Margitta Retz, Christina Wiemers, et al.
Page
of 10